Printed from Voxsanity (voxsanity.com.au) — NCT06816966 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
Back to Lung Cancer
Phase 2 Lung Cancer Trial, By Invitation
NCT06816966
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- People who have been diagnosed with extensive-stage small cell lung cancer (ES-SCLC), confirmed by laboratory testing of tissue from the original tumour or a secondary site.
- People who have measurable areas of cancer and no more than 3 visible spots of cancer in the liver.
- People who have fluid around the lungs, but only if testing of that fluid showed no cancer cells, or if there was too little fluid to safely test and it did not show abnormal activity on imaging scans.
- People aged 18 years or older.
- People whose general physical functioning falls within a certain range on a standard medical scale (called ECOG performance status 0–2, meaning able to carry out daily activities with at most limited restriction — confirm with trial site).
- People whose organs and bone marrow are functioning well enough to meet the trial's requirements (confirm with trial site for specific levels).
- People who, or whose legal representative, have given written agreement to take part in the study before joining.
- People with a life expectancy of more than six months.
- People who have a history of an autoimmune condition that has not been active for more than 3 years and who are not currently taking immune-suppressing medications such as methotrexate or steroids above the equivalent of 10 mg of prednisone daily.
- People with a history of an underactive thyroid caused by an autoimmune condition, who are on a stable dose of thyroid replacement medication.
- People with controlled type 1 diabetes who are on a stable insulin plan.
- People with skin conditions such as eczema, psoriasis, lichen simplex chronicus, or vitiligo, as long as the condition is not currently causing a flare-up and the person has not been on immune-suppressing medications for it in the 12 months before joining.
- People with other serious health conditions, known or suspected, may still be considered unless those conditions make it unsafe to receive radiation, chemotherapy, or immune therapy, or could interfere with the trial results — eligibility in this area will be assessed individually (confirm with trial site).
- People with a past hepatitis B infection that has resolved (shown by a negative surface antigen test and a positive core antibody test) are eligible.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People who have more than 3 spots of cancer spread to the liver.
- People who have cancer-related fluid around the lungs (malignant pleural effusion) or around the heart (pericardial effusion).
- People who have previously had radiation therapy to the chest in a way that would overlap with the radiation fields planned in this trial.
- People with an active autoimmune disease, including but not limited to lupus, rheumatoid arthritis, inflammatory bowel disease (such as Crohn's disease or ulcerative colitis), antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis.
- People with a known condition that weakens the immune system, such as a history of bone marrow transplant or a condition called chronic lymphocytic leukaemia (CLL).
- People with chronic obstructive pulmonary disease (COPD) who need more than 10 mg of prednisone (or equivalent) daily by mouth at the time of joining — note that inhaled steroids do not count as an exclusion.
- People who have been hospitalised for unstable chest pain or heart failure in the last 3 months.
- People who have had a heart attack in the 6 months before joining the trial.
- People with a significant lung condition involving scarring or inflammation of the lung tissue (interstitial lung disease).
- People who have received a donor organ transplant.
- People who are HIV-positive and do not meet specific requirements around viral load and medication stability, or who currently need antibiotics or antifungal medications to prevent infections (confirm with trial site for full details).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Status
By Invitation
Phase
Phase 2
Sponsor
Fujian Medical University Union Hospital
Registry
ClinicalTrials.gov
Start date
26 December 2023
Est. completion
31 October 2026
Where this trial is recruiting
🇨🇳 China
Primary endpoints
6-month Progression-Free Survival rate; Safety
Can't join this trial?
Data last synced from ClinicalTrials.gov: 10 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.